Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CALCRL | Q16602 | 7/20 | 0.34 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 2/20 | 0.33 |
| ▸ | CCR3 | P51677 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5088904 | 1.00 | DRD2 (0.36) | DRD2DRD4DRD3CALCRLRAMP1 | |
| SCHEMBL5088963 | 0.89 | DRD2 (0.39) | DRD2DRD4DRD3CALCRLRAMP1 | |
| SCHEMBL5088970 | 0.89 | DRD2 (0.39) | DRD2DRD4DRD3CALCRLRAMP1 | |
| SCHEMBL5091185 | 0.88 | DRD2 (0.46) | DRD2DRD4DRD3CALCRLRAMP1 | |
| SCHEMBL5091183 | 0.88 | DRD2 (0.46) | DRD2DRD4DRD3CALCRLRAMP1 | |
| SCHEMBL5091123 | 0.87 | CALCRL (0.38) | DRD2DRD4DRD3CALCRLRAMP1 | |
| SCHEMBL5091122 | 0.87 | CALCRL (0.38) | DRD2DRD4DRD3CALCRLRAMP1 | |
| SCHEMBL5091154 | 0.85 | CALCRL (0.43) | DRD2DRD4DRD3CALCRLRAMP1 | |
| SCHEMBL5091156 | 0.85 | CALCRL (0.43) | DRD2DRD4DRD3CALCRLRAMP1 | |
| SCHEMBL5098336 | 0.84 | HSD11B1 (0.38) | DRD2DRD4DRD3CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407963-B2 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-08-05 | — | — | US | claimed |
| EP-1228059-B1 | NOVEL CYCLOPROPANES AS CGRP ANTAGONISTS, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-03 | — | — | EP | claimed |
| US-7407963-B2 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-08-05 | — | — | US | disclosed |
| EP-1228059-B1 | NOVEL CYCLOPROPANES AS CGRP ANTAGONISTS, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20030139417-A1 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139417-A1 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | CALCA, CALCRL, CALCB | DRD2 640/4885DRD4 1077/4885DRD3 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.